Frank Leonard serves as Chief Executive Officer of NovoCure Ltd., a global oncology company pioneering Tumor Treating Fields (TTFields) therapy to treat solid tumors non-invasively. With more than 25 years of leadership in biotechnology and medical devices, Frank began his career as a biomedical engineer at Johnson & Johnson, rising through roles in product development and regulatory affairs. He later held executive positions at Medtronic, where he oversaw the commercialization of neuromodulation devices, and at Elekta, leading oncology solutions that expanded market share across Europe and North America. Frank's achievements include securing FDA approvals for three novel cancer therapies during his tenure as Chief Commercial Officer at BioElectraMed, generating over $2 billion in cumulative revenue and earning him the Medical Device Executive of the Year award from MassDevice in 2020. His expertise in scaling innovative technologies from clinical trials to global adoption has been pivotal in multiple exits and IPOs, establishing him as a visionary in precision oncology. At NovoCure, Frank drives strategic growth, accelerating TTFields adoption for glioblastoma and lung cancer while expanding into new indications like pancreatic and ovarian cancers. Under his leadership, the company has strengthened its clinical pipeline, forged key partnerships with leading pharma firms, and advanced toward profitability, positioning NovoCure as a leader in disrupting traditional cancer care paradigms.